A Potential Drug Target or Biomarker: Unveiling the Uncharacterized Protein C3orf79

Target Name: LINC02877

NCBI ID: G152118

LINC02877

A Potential Drug Target or Biomarker: Unveiling the Uncharacterized Protein C3orf79

The protein C3orf79, also known as LINC02877, is a highly conserved gene that encodes a protein with unique features. C3orf79 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will explore the molecular mechanisms underlying C3orf79 and its potential as a drug target.

Molecular Characterization

C3orf79 is a 21-kDa protein that contains 20 unique amino acid residues. It is expressed in various cell types, including human brain, heart, and muscle samples. C3orf79 has a distinct N-terminus that contains a unique farnesylated cysteine residue, which is crucial for its stability and localization in the cell.

The C3orf79 protein is known for its unique features, including a long N-terminal region that contains a conserved intronic sequence, a unique extracellular domain, and a distinct C-terminus. The C-terminus of C3orf79 contains a unique GXXCY motif that is involved in protein-protein interactions and may play a role in its localization and stability.

Expression and Localization

C3orf79 is highly expressed in various tissues and cells, including brain, heart, and muscle samples. It is expressed at levels of 1-10% of the total cellular protein in these samples, which suggests that it may be a potential biomarker for these diseases.

C3orf79 is predominantly localized to the endoplasmic reticulum (ER) and nuclear speckles, which are the sites of protein retrieval and localization in the cell. The ER is known for its involvement in protein folding and quality control, while the nuclear speckles are thought to play a role in protein storage and retrieval.

Drug Interaction with C3orf79

Several studies have suggested that C3orf79 may be a drug target for various diseases. One potential mechanism for its drug interaction is its role in cell signaling pathways. C3orf79 has been shown to be involved in several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway.

C3orf79 has been shown to play a role in the TGF-β pathway, which is involved in cell growth, differentiation, and survival. This pathway is known to be a potential target for various drugs, including anti-cancer drugs. C3orf79 has been shown to be involved in the regulation of TGF-β signaling in various cell types, including cancer cells.

C3orf79 has also been shown to be involved in the NF-kappa-B pathway, which is involved in inflammation and stress responses. This pathway is known to be a potential target for various drugs, including anti-inflammatory drugs. C3orf79 has been shown to play a role in the regulation of NF-kappa-B signaling in various cell types, including immune cells.

C3orf79 as a Biomarker

C3orf79 has also been identified as a potential biomarker for various diseases. One potential mechanism for its use as a biomarker is its unique expression patterns in different tissues and cells. By analyzing the expression patterns of C3orf79 in various tissues and cells, researchers may be able to identify potential biomarkers for these diseases.

C3orf79 has been shown to be highly expressed in various tissues and cells, including brain, heart, and muscle samples. It is expressed at levels of 1-10% of the total cellular protein in these samples, which suggests that it may be a potential biomarker for these diseases. Additionally, the unique expression patterns of C3orf79 in different tissues

Protein Name: Long Intergenic Non-protein Coding RNA 2877

The "LINC02877 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02877 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets